All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Medicare announces coverage of chimeric antigen receptor (CAR) T-cell therapy in the United States (US)

Aug 12, 2019

Bookmark this article

Chimeric antigen receptor (CAR) T-cell therapy is a highly personalized treatment approved by the United States (US) Food & Drug Administration (FDA) for the treatment of certain types of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and pediatric R/R acute lymphoblastic leukemia (ALL). CAR T products are also being developed, or are in clinical trials, in other indications such as additional hematological malignancies and solid tumors.1-4 The two FDA approved CAR T therapies are tisagenlecleucel, which is licensed for R/R diffuse large B-cell lymphoma (DLBCL) and R/R pediatric ALL, and axicabtagene ciloleucel, approved in R/R DLBCL, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma and DLBCL that results from follicular lymphoma.1-4 These CAR T products were also approved by the European Medicines Agency (EMA) in August 2018.5,6

CAR T therapy involves removing a patient’s T-cells via apheresis, genetically modifying them to express a CAR, and then reinfusing the cells into the patient. Due to the personalized aspect of the therapy, there are significant associated costs. The current list price for axicabtagene ciloleucel is $373,000, and tisagenlecleucel is $475,000.5 This is true for the treatment-associated costs such as product manufacturing and delivery, but there are also additional costs associated with any inpatient admissions as well as the patient-associated costs such as travel to, and from, the hospital.

It has now been announced by the Centers for Medicare and Medicaid Services (CMS), that Medicare will pay for CAR T therapies. This will cover associated costs, as well as that of the therapy itself including: administration of the drug, apheresis to collect the cells, the manufacturing of the cells, and the reinfusion into the patient. Additionally, Medicare will cover outpatient or inpatient care. The treatment must take place at certified healthcare facilities which are enrolled in the Risk Evaluation and Mitigation Strategies (REMS) program which is FDA-mandated. Furthermore, Medicare will support the use of CAR T in an FDA approved indication or for other uses when the product is FDA-approved and the use is supported in ≥ one CMS-approved compendia.7,8 The American Society for Hematology (ASH) have supported this decision in a comment The Washington Post.

Whilst CAR T is not currently approved for the treatment of multiple myeloma (MM), there are many ongoing trials of CAR T products for R/R MM. Click the links to read more about the latest clinical data from CAR T trials in MM and when to use CAR T in MM

  1. Martinez M., Kyung Moon E. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol. 2019 Feb 05. DOI: 10.3389/fimmu.2019.00128
  2. FDA. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. [Accessed 2019 Aug 09]
  3. FDA. FDA approval brings first gene therapy to the United States. [Accessed 2019 Aug 09]
  4. FDA. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. [Accessed 2019 Aug 09]
  5. European Medicines Agency. Kymriah. [Accessed 2019 Aug 09] 
  6. European Medicines Agency. Yescarta. [Accessed 2019 Aug 09]
  7. Fierce Pharma. Medicare's new CAR-T coverage rules could boost adoption of slow-growing meds. Fierce Pharma link. [Accessed 2019 Aug 09] 
  8. Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). [Accessed 2019 Aug 09]
  9. The Washington Post. Medicare will cover pioneering cancer treatment nationwide. [Accessed 2019 Aug 08]

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
16 votes - 16 days left ...


Subscribe to get the best content related to multiple myeloma delivered to your inbox